Greenwich LifeSciences, Inc. (GLSI)

Market Cap	176.02M
Revenue (ttm)	n/a
Net Income (ttm)	-7.40M
Shares Out	12.82M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,964
Open	13.78
Previous Close	13.7
Day's Range	12.85 - 13.84
52-Week Range	6.82 - 33.8
Beta	3.71
Analysts	Buy
Price Target	79.56 (+512.9%)
Earnings Date	Nov 21, 2022

About GLSI

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 ...

• Industry: Biotechnology
• IPO Date: Sep 25, 2020
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: GLSI

Analyst Forecast

According to 7 analysts, the average rating for GLSI stock is "Buy." The 12-month stock price forecast is 79.56, which is an increase of 512.94% from the latest price.

Price Target

$79.56

(512.94% upside)

Analyst Consensus: Buy